PAVmed

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.

NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent UK-based global industry executive, Debbie White, to its Board of Directors. Ms. White will serve on the Company's Audit and Compensation Committees.

Global Industry Executive Debbie White Joins PAVmed Board of Directors

Evogene

Savara

Synlogic

Analysts say these penny stocks are a buy right now & have bullish price targets to boot. The post Penny Stocks To Buy According To Analysts With Price Targets Up to 341% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy According To Analysts With Price Targets Up to 341%

NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a commercial-stage, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer and Executive Chairman of its majority-owned subsidiary, Lucid Diagnostics Inc., was selected as one of the Top 50 Healthcare Technology CEOs of 2021 by Healthcare Technology Report.

PAVmed Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO by Healthcare Technology Report

NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer will present a corporate update at the 20th Annual Needham Healthcare Conference on April 15, 2021 at 8:00 AM EDT.

PAVmed to Present at the 20th Annual Needham Healthcare Conference

On-demand corporate presentation scheduled for March 17, 2021

PAVmed to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

PAVmed has significant room to grow in the next year with their extensive pipeline for a range of clinical conditions, with an addressable market of over $3 billion. The company has recognizable and successful management led by Lishan Aklog, with the recent addition of Stanley Lapidus as a special advisor, the founder of Exact Sciences.

PAVmed Primed To Deliver Significant Value For Shareholders

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has retired all of the Company's outstanding convertible debt, applying approximately $14.5 million of the proceeds of its recent underwritten common stock offering to pay the full outstanding balance of all of its convertible notes, which were held by Alto Opportunity Master Fund.

PAVmed Retires Convertible Debt

NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the Advanced Medical Technology Association (AdvaMed), the world's leading medical technology trade association, has appointed Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer to its Board of Directors.

PAVmed Chairman and Chief Executive Officer Lishan Aklog, M.D., Elected to AdvaMed Board of Directors

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced underwritten public offering (the “Offering”) of approximately 9.8 million shares of its common stock for gross proceeds of approximately $45 million, before deducting underwriting discounts and commissions and other offering expenses payable by PAVmed.

PAVmed Announces Closing of its Public Offering of Common Stock

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of approximately 9.8 million shares of its common stock for gross proceeds of approximately $45 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by PAVmed. The Offering is expected to close on or about February 25, 2021, subject to customary closing conditions. In addition, PAVmed has granted the underwriter of the Offering a 30-day option to purchase up to approximately 1.5 million additional shares of its common stock.

PAVmed Announces Pricing of $45 Million Public Offering of Common Stock

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it is commencing an underwritten public offering of its common stock (the “Offering”). PAVmed also expects to grant to the underwriter for the Offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering. All of the shares to be sold in the Offering will be sold by PAVmed, subject to customary closing conditions. PAVmed intends to use the net proceeds from the Offering to repay all of the Company's outstanding debt, including all outstanding convertible notes (subject to our agreeing with the holder of such notes on the terms of repayment), with the balance to be used for working capital and general corporate purposes.

PAVmed Announces Proposed Public Offering of Common Stock

PAVmed's (PAVM) CEO Lishan Aklog on Business Update and Preliminary Q4 2020 Results - Earnings Call Transcript

Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company

PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results

Conference call and live webcast was previously scheduled for 4:30 PM EST

PAVmed Reschedules Business Update Conference Call on February 22, 2021 to 8:30 AM EST

NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the first U.S. patient recently underwent successful carpal tunnel release using its CarpX® minimally invasive carpal tunnel device.

First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed's CarpX® Device

PAVmed has a suite of medical devices that could improve on the current standard of care in multiple areas. Based on the opportunity in esophageal cancer screening alone, the company looks substantially undervalued with a current market cap of just $135 million.

PAVmed's Esophageal Diagnostic Tools Should Create Strong Shareholder Value

NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Monday, February 22, 2021 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company's near-term milestones and growth strategy. In addition, Dennis McGrath, the Company's President and Chief Financial Officer, will discuss fourth quarter 2020 financial results.

PAVmed to Hold Business Update Conference Call on February 22, 2021

NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct offering (the “Offering”) of 6.0 million shares of common stock at a price of $2.24 per share which was priced at-the-market under Nasdaq rules.

PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of 6.0 million shares of common stock at a price of $2.24 per share for gross proceeds of approximately $13.4 million in a registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules.

PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules

NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct offering (the “Offering”) of approximately 5.1 million shares of common stock at a price of $1.60 per share.

PAVmed Closes Additional $8.1 Million Common Stock Registered Direct Offering

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of approximately 5.1 million shares of common stock in a registered direct offering with predominantly existing institutional investors at a price of $1.60 per share for gross proceeds of $8.1 million.

PAVmed Announces Pricing of Additional $8.1 Million Common Stock Registered Direct Offering

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of 5.6 million shares of common stock in a registered direct offering at a price of $1.60 per share for gross proceeds of approximately $8.9 million.

PAVmed Announces Registered Direct Offering of its Common Stock

PAVmed's (PAVM) CEO Lishan Aklog on Q3 2020 Results - Earnings Call Transcript

Conference call to be held today at 4:30 p.m. Eastern time

PAVmed Reports Third Quarter 2020 Financial Results and Provides Business Update

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Tuesday, November 17, 2020 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company's near-term milestones and growth strategy. In addition, Dennis McGrath, the Company's President and Chief Financial Officer, will discuss third quarter 2020 financial results.

News for PAVmed Stock (PAVM)